Alector (NASDAQ: ALEC) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Alector to related businesses based on the strength of its earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Institutional & Insider Ownership
47.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings for Alector and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alector currently has a consensus target price of $26.67, indicating a potential upside of 8.01%. As a group, “Biological products, except diagnostic” companies have a potential upside of 34.04%. Given Alector’s competitors higher possible upside, analysts plainly believe Alector has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Alector and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Alector Competitors||$897.63 million||$190.37 million||-1.33|
Alector’s competitors have higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Alector and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Alector competitors beat Alector on 6 of the 11 factors compared.
Alector Company Profile
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of Alzheimer's and Parkinson's diseases; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under preclinical research stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.